Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04382326 · ClinicalTrials.gov registry record · Phase 3
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,997
- Enrollment target
NCT04382326 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,997 participants.
The verdict
NCT04382326, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,997 participants
- Enrollment target
Study Summary
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Interventions
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine
- BIOLOGICAL 13-valent pneumococcal conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,997 participants |
| Start Date | 2020-05-20 |
| Est. Completion | 2022-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04382326
The ClinicalTrials.gov registry entry for NCT04382326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,997 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 20-valent pneumococcal conjugate vaccine is the first listed.
NCT04382326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04382326 about?
NCT04382326 is a clinical study titled "20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants". 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
What is the current status of trial NCT04382326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,997 participants. The study started on 2020-05-20. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT04382326?
The interventions under investigation include: 20-valent pneumococcal conjugate vaccine (BIOLOGICAL), 13-valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04382326?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.